News Archive - Navrogen : Navrogen

July 14, 2026

Navrogen Awarded Key Patent in China for NAV-001: An Innovative Anti-Mesothelin Antibody-Drug Conjugate (ADC) Targeting Difficult-to-Treat Cancer

The patent covers the design and use of NAV-001 ADC to treat cancers where the therapeutic efficacy of antibody-based drugs, including ADCs, is immunosuppressed.

July 8, 2026

Navrogen Publishes Breakthrough on NAV-005, A CA125 Antagonist That Improves Antibody Cancer Therapy and ADC Efficacy

The research highlights how NAV-005 overcomes the immunosuppressive effects that tumor-produced CA125 has on antibodies and ADCs to enhance their efficacy against tumor cells

January 20, 2026

Navrogen Granted Composition of Matter and Use Patent to Humoral Immuno-Oncology (HIO) Factor Antagonist NAV-005 for the Treatment of Cancer

Navrogen, Inc. announced the issuance of U.S. Patent No. 12,516,096 covering NAV-005, a humoral immuno-oncology factor antagonist designed to overcome antibody suppression in multiple cancer types.

October 30, 2025

Navrogen Granted International Patents Covering Its Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate

Navrogen, Inc. announced the grant of European and Japanese patents covering its HIO platform technology and lead therapeutic NAV-001, an HIO-refractory ADC targeting mesothelin-expressing cancers.

September 29, 2025

Navrogen Granted Patent to Develop Antibodies and Next Gen Antibody Formats That Are Refractory to Immunosuppressive Humoral Immuno-Oncology (HIO) Factors

Navrogen, Inc. announced the issuance of U.S. Patent No. 12,416,642 covering its platform technology for detecting HIO-susceptible antibodies and engineering HIO-refractory cancer therapeutics.

September 8, 2025

Navrogen Awarded National Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology (HIO) Positive Cancers

Navrogen, Inc. announced an NCI grant award to advance development of antagonists targeting HIO-positive cancers, supporting therapies designed to overcome tumor-driven humoral immunosuppression.